In conclusion, our work revealed at least that TRs are active in BRCA1 associated breast cancer, that TRβ expression in BRCA1 mutant tumor samples is associated with a prolonged overall survival, and that both TRs may arise as interesting alternative targets for endocrine treatment of BRCA1 associated triple negative breast cancer. This evidence concerns the gene BRCA1 and breast cancer.